Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter favorable biodistribution profile in non-human primates using a clinically validated editing strategy
You might also be interested in reading Bitcoin Plunges Below $41K as ‘Sell the Bitcoin ETF News’ Wins the Day.